Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease
β Scribed by Glenn J. Shamdas; Frederick R. Ahmann; Monika B. Matzner; Justine M. Ritchie
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 633 KB
- Volume
- 71
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract The antiβandrogens used in prostate cancer therapy have been designed to interfere with the normal androgen receptor (AR)βmediated processes that ensure prostate cell survival, triggering tumor cells to undergo programmed cell death. While antiβandrogens were originally designed to trea
## BACKGROUND. Infusion of dendritic cells (DCs) pulsed with PSMA peptides was considered possible in hormone-refractory metastatic prostate cancer patients both with or without prior treatment with a greater number of DCs and for lesser infusions than previously administered. METHODS. DCs + PSMA p
BACKGROUND. ) is a cytokine that plays a central role in host defense due to its wide range of immune and hematopoietic activities. It is found in high levels in human ejaculate, and has recently been found to regulate prostate-specific protein expression in prostate cancer cells through nonsteroida